Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Jasoprim, Malirid, Neo-Quipenyl, Pimaquin, Pmq, Primachina, Primacin, Primaquina, Primaquine, Primaquine diphosphate, Primaquine Phosphate, and Remaquin
Disease: Malaria, Plasmodium vivax, Plasmodium ovale
Drug Class: Antimalarial
Related Files: Carboxyprimaquine (metabolite)
Date Updated: March 2022
|
Absorption Model |
|
|
Volume of Distribution |
|
|
Routes of Elimination |
|
|
Perpetrator DDI |
|
|
Validation |
|
|
Limitations |
|
|
Updates in Version 19 |
|
Simcyp developed Aprepitant compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.
Simcyp developed tizanidine compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.
The 4β-hydroxycholesterol (4β-OHC) file is an endogenous biomarker for CYP3A activity mainly measured to evaluated potential CYP3A induction in vivo. The 4β-OHC file was developed as a primary metabolite of the parent compound, cholesterol. As the compound requires specific system parameter inputs for endogenous CYP abundance scaling, the parent-metabolite file is available within a workspace containing the required system parameters. The parent-metabolite file has been developed in the Simcyp Simulator V23 and details of the file performance are described in Karkhanis et al., 2024 (PMID 39458613) and in a compound summary that provides the key pharmacokinetic features of cholesterol and 4β-OHC considered within the model.
|
7 |